Literature DB >> 35440099

Body mass index associated with monoclonal gammopathy of undetermined significance (MGUS) progression in Olmsted County, Minnesota.

Geffen Kleinstern1,2, Dirk R Larson2, Cristine Allmer2, Aaron D Norman2, Grace Muntifering3, Jason Sinnwell2, Alissa Visram4,5, Vincent Rajkumar4, Angela Dispenzieri4, Robert A Kyle4, Susan L Slager2,4, Shaji Kumar4, Celine M Vachon6.   

Abstract

Monoclonal gammopathy of undetermined significance (MGUS) is a premalignant clonal disorder that progresses to multiple myeloma (MM), or other plasma-cell or lymphoid disorders at a rate of 1%/year. We evaluate the contribution of body mass index (BMI) to MGUS progression beyond established clinical factors in a population-based study. We identified 594 MGUS through a population-based screening study in Olmsted County, Minnesota, between 1995 and 2003. Follow-up time was calculated from the date of MGUS to last follow-up, death, or progression to MM/another plasma-cell/lymphoid disorder. BMI (kg/m2 < 25/≥25) was measured close to screening date. We used Cox regression to estimate hazard ratios (HR) and 95% confidence intervals (CI) for the association of BMI ≥ 25 versus BMI < 25 with MGUS progression and also evaluated the corresponding c-statistic and 95% CI to describe discrimination of the model for MGUS progression. Median follow-up was 10.5 years (range:0-25), while 465 patients died and 57 progressed and developed MM (N = 39), AL amyloidosis (N = 8), lymphoma (N = 5), or Waldenstrom-macroglobulinemia (N = 5). In univariate analyses, BMI ≥ 25 (HR = 2.14,CI:1.05-4.36, P = 0.04), non-IgG (HR = 2.84, CI:1.68-4.80, P = 0.0001), high monoclonal (M) protein (HR = 2.57, CI:1.50-4.42, P = 0.001), and abnormal free light chain ratio (FLCr) (HR = 3.39, CI:1.98-5.82, P < 0.0001) were associated with increased risk of MGUS progression, and were independently associated in a multivariable model (c-statistic = 0.75, CI:0.68-0.82). The BMI association was stronger among females (HR = 3.55, CI:1.06-11.9, P = 0.04) vs. males (HR = 1.39, CI:0.57-3.36, P = 0.47), although the interaction between BMI and sex was not significant (P = 0.15). In conclusion, high BMI is a prognostic factor for MGUS progression, independent of isotype, M protein, and FLCr. This association may be stronger among females.
© 2022. The Author(s).

Entities:  

Mesh:

Year:  2022        PMID: 35440099      PMCID: PMC9018764          DOI: 10.1038/s41408-022-00659-9

Source DB:  PubMed          Journal:  Blood Cancer J        ISSN: 2044-5385            Impact factor:   9.812


  34 in total

1.  Interleukin-6-related genotypes, body mass index, and risk of multiple myeloma and plasmacytoma.

Authors:  Wendy Cozen; Mulugeta Gebregziabher; David V Conti; David J Van Den Berg; Gerhard A Coetzee; Sophia S Wang; Nathaniel Rothman; Leslie Bernstein; Patricia Hartge; Ann Morhbacher; Simon G Coetzee; Muhammad T Salam; Wei Wang; John Zadnick; Sue A Ingles
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-11       Impact factor: 4.254

Review 2.  Body mass index and risk of multiple myeloma: a meta-analysis of prospective studies.

Authors:  Alice Wallin; Susanna C Larsson
Journal:  Eur J Cancer       Date:  2011-02-25       Impact factor: 9.162

3.  Anthropometric characteristics, physical activity and risk of hematological malignancies: A systematic review and meta-analysis of cohort studies.

Authors:  Theodora Psaltopoulou; Theodoros N Sergentanis; Ioannis Ntanasis-Stathopoulos; Ioannis-Georgios Tzanninis; Elena Riza; Meletios A Dimopoulos
Journal:  Int J Cancer       Date:  2019-02-12       Impact factor: 7.396

4.  Body Fatness and Cancer--Viewpoint of the IARC Working Group.

Authors:  Béatrice Lauby-Secretan; Chiara Scoccianti; Dana Loomis; Yann Grosse; Franca Bianchini; Kurt Straif
Journal:  N Engl J Med       Date:  2016-08-25       Impact factor: 91.245

5.  Host-derived adiponectin is tumor-suppressive and a novel therapeutic target for multiple myeloma and the associated bone disease.

Authors:  Jessica A Fowler; Seint T Lwin; Matthew T Drake; James R Edwards; Robert A Kyle; Gregory R Mundy; Claire M Edwards
Journal:  Blood       Date:  2011-09-08       Impact factor: 22.113

6.  Abdominal adipose tissue in MGUS and multiple myeloma.

Authors:  Joyce Veld; Elizabeth K O'Donnell; Michaela R Reagan; Andrew J Yee; Martin Torriani; Clifford J Rosen; Miriam A Bredella
Journal:  Skeletal Radiol       Date:  2016-06-25       Impact factor: 2.199

7.  Obesity and multiple myeloma.

Authors:  G D Friedman; L J Herrinton
Journal:  Cancer Causes Control       Date:  1994-09       Impact factor: 2.506

8.  Effect of statins, smoking and obesity on progression of monoclonal gammopathy of undetermined significance: a case-control study.

Authors:  Michael A Thompson; Robert A Kyle; L Joseph Melton; Matthew F Plevak; S Vincent Rajkumar
Journal:  Haematologica       Date:  2004-05       Impact factor: 9.941

9.  Body mass index throughout adulthood, physical activity, and risk of multiple myeloma: a prospective analysis in three large cohorts.

Authors:  Catherine R Marinac; Brenda M Birmann; I-Min Lee; Bernard A Rosner; Mary K Townsend; Edward Giovannucci; Timothy R Rebbeck; Julie E Buring; Graham A Colditz
Journal:  Br J Cancer       Date:  2018-03-12       Impact factor: 7.640

Review 10.  Obesity as a Possible Risk Factor for Progression from Monoclonal Gammopathy of Undetermined Significance Progression into Multiple Myeloma: Could Myeloma Be Prevented with Metformin Treatment?

Authors:  Ademar Dantas da Cunha Júnior; Dalila Luciola Zanette; Fernando Vieira Pericole; Sara Teresinha Olalla Saad; José Barreto Campello Carvalheira
Journal:  Adv Hematol       Date:  2021-01-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.